Laura van ‘t Veer, PhD, and colleagues at the Netherlands Cancer
Institute, Amsterdam, recently identified a 70-gene profile that could predict
cancer recurrence in a subset of women who had node-negative breast cancer.
Their studies will be the foundation of an upcoming clinical trial in Europe
and Latin America that will use DNA microarray technology (which provides
a snapshot of what genes are expressed, or active, in normal and cancerous
cells) to help determine therapies for women with this disease (JAMA. 2004;291:2927-2930).
She took a break during the American Society of Clinical Oncology annual meeting
in New Orleans to talk about her work.
Hampton T. Laura van ‘t Veer, PhD. JAMA. 2004;292(6):675. doi:10.1001/jama.292.6.675